Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amazon.com Inc (AMZN) vs BioNano Genomics Inc (BNGO) Price & Performance

Amazon.com IncTrade
BioNano Genomics IncTrade

Price performance (Past 24H)

Key statistics

Amazon.com Inc vs BioNano Genomics Inc — how do they compare? Amazon.com Inc trades at $267.65 (market cap $2.94T), while BioNano Genomics Inc trades at $1.18 (market cap $13.66M). The key difference: Amazon.com Inc is far larger — about 215226.9× BioNano Genomics Inc's market cap, and Amazon.com Inc is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.

AMZNBNGO
Market Cap
$2.94T$13.66M
Volume
3,931,282
Sector
Consumer CyclicalHealth
52-Week High
$284.02$4.92
52-Week Low
$198.79$1.06
Enterprise Value
$3.04T$16.26M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amazon.com Inc

Amazon (AMZN) trades at $272.27, down 2.09% today but maintains strong fundamentals with robust revenue growth from $638B in 2024 to $716.9B in 2025 and net income surging to $77.67B. Technical indicators show a bullish trend with support at $271 and resistance at $275, while analyst consensus remains overwhelmingly positive with 89% buy ratings and a $333.86 price target. Recent news highlights CEO Andy Jassy's optimistic outlook on AWS growth and AI chip business expansion.

Amazon presents a compelling investment case with accelerating profitability and dominant market positioning, though investors face risks from intense competition and significant capital expenditures. The stock's current valuation at 21.9x P/E appears reasonable given projected 2026 net income growth to $135.3B, supporting potential upside to analyst targets despite near-term market volatility.

BioNano Genomics Inc

BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.

The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amazon.com Inc

Amazon.com, Inc. is an online retailer that offers a wide range of products. The Company products include books, music, computers, electronics and numerous other products. Amazon offers personalized shopping services, Web-based credit card payment, and direct shipping to customers. Amazon also operates a cloud platform offering services globally.

Read more on AMZN

About BioNano Genomics Inc

Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.

Read more on BNGO